Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392110 | 1.00 | FAAH (0.70) | FAAHPSMB5EPHX2CNR1CNR2 | |
| SCHEMBL28518103 | 0.88 | PSMB5 (0.68) | FAAHPSMB5 | |
| SCHEMBL28518104 | 0.88 | PSMB5 (0.68) | FAAHPSMB5 | |
| SCHEMBL15285471 | 0.87 | FAAH (0.91) | FAAHPSMB5EPHX2CNR1CNR2 | |
| SCHEMBL22494088 | 0.87 | FAAH (0.91) | FAAHPSMB5EPHX2CNR1CNR2 | |
| SCHEMBL22494089 | 0.87 | FAAH (0.91) | FAAHPSMB5EPHX2CNR1CNR2 | |
| SCHEMBL22494087 | 0.87 | FAAH (0.91) | FAAHPSMB5EPHX2CNR1CNR2 | |
| SCHEMBL22494099 | 0.87 | FAAH (0.91) | FAAHPSMB5EPHX2CNR1CNR2 | |
| SCHEMBL22494109 | 0.87 | FAAH (0.91) | FAAHPSMB5EPHX2CNR1CNR2 | |
| SCHEMBL22494098 | 0.87 | FAAH (0.91) | FAAHPSMB5EPHX2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG | 2009-12-31 | — | — | US | disclosed |
| EP-2123283-A1 | THE TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER EFFECT | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | GLS2, GLS, VIP | FAAH 1064/4885PSMB5 3210/4885EPHX2 3917/4885 |
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ALAD, SLC27A2, ANTXR2 | FAAH 342/4885PSMB5 3138/4885EPHX2 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.